troglitazone has been researched along with Breast Cancer in 31 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer." | 9.10 | Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. ( Burstein, HJ; Demetri, GD; Mueller, E; Sarraf, P; Spiegelman, BM; Winer, EP, 2003) |
| " We focused on Δ2-troglitazone (Δ2-TGZ), a PPARγ inactive TZD that affects breast cancer cell viability." | 7.81 | PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells. ( Boisbrun, M; Cerella, C; Chapleur, Y; Chbicheb, S; Colin-Cassin, C; Diederich, M; Flament, S; Grillier-Vuissoz, I; Kuntz, S; Mazerbourg, S; Yao, X, 2015) |
| "We studied the roles of glycolysis and glutaminolysis following an acute reduction in mitochondrial membrane potential (Ψ(m)) induced by the thiazolidinedione troglitazone (TRO) and compared the responses with CCCP-induced depolarization in breast cancer derived MCF-7 and MDA-MB-231 cells as well as in the MCF-10A normal breast cell line." | 7.77 | Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: Relationship to mitochondrial membrane potential. ( Friday, E; Oliver, R; Turturro, F; Welbourne, T, 2011) |
| "In this study, we investigated the effect of the PPARgamma ligand, troglitazone, on telomerase activity in the MDA-MB-231 breast cancer cell line." | 7.76 | Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. ( Done, SJ; Harrington, LA; Nguyen, J; Rashid-Kolvear, F; Taboski, MA; Wang, DY, 2010) |
| "We previously showed that troglitazone (TRO) induces a profound cellular acidosis in MCF-7 cells as a result of inhibiting Na(+)/H(+) exchanger (NHE)1-mediated acid extrusion and this was associated with a marked reduction in cellular proliferation." | 7.74 | Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na+/H+ exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7. ( Friday, E; Oliver, R; Turturro, F; Welbourne, T, 2007) |
| "In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and ciglitazone on cyclin D1 repression." | 7.73 | Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. ( Brueggemeier, RW; Chen, CS; Chen, KF; Huang, JW; Kulp, SK; Shapiro, CL; Shiau, CW; Yang, YT, 2005) |
| "The effect of epirubicin on inhibiting cell proliferation of breast cancer cells was enhanced by co-treatment with troglitazone in the range of 4 micromol/L to 24 micromol/L." | 7.73 | [Troglitazone sensitizes effect of epirubicin on breast cancer cells]. ( Lv, JH; Meng, ZX; Sun, JX; Sun, YJ, 2006) |
| "We previously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells." | 7.72 | Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. ( Blaschke, F; Bruemmer, D; Herle, AJ; Hsueh, WA; Law, RE; Yin, F, 2004) |
| "The purpose of this study was to assess whether troglitazone (TRO) would induce cellular acidosis by inhibiting Na(+)/H(+) exchanger (NHE) 1 in breast carcinoma-derived cell lines and, if so, whether cellular acidosis would be associated with a reduction in proliferation." | 7.72 | Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. ( Fowler, R; Friday, E; Surie, D; Turturro, F; Welbourne, T, 2004) |
| "2‑Deoxyglucose (2‑DG) was more cytotoxic in CT26 cancer cells compared with T47D cells, despite a smaller suppression of glucose uptake." | 5.56 | Troglitazone exerts metabolic and antitumor effects on T47D breast cancer cells by suppressing mitochondrial pyruvate availability. ( Cho, YS; Jung, KH; Lee, JH; Lee, KH; Moon, SH; Park, JW, 2020) |
| "Breast cancer is the most prevalent cancer in women." | 5.38 | Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. ( Boisbrun, M; Chapleur, Y; Colin, C; Flament, S; Grillier-Vuissoz, I; Kuntz, S; Martin, H; Mazerbourg, S; Richert, L; Salamone, S, 2012) |
| "To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer." | 5.10 | Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. ( Burstein, HJ; Demetri, GD; Mueller, E; Sarraf, P; Spiegelman, BM; Winer, EP, 2003) |
| " We focused on Δ2-troglitazone (Δ2-TGZ), a PPARγ inactive TZD that affects breast cancer cell viability." | 3.81 | PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells. ( Boisbrun, M; Cerella, C; Chapleur, Y; Chbicheb, S; Colin-Cassin, C; Diederich, M; Flament, S; Grillier-Vuissoz, I; Kuntz, S; Mazerbourg, S; Yao, X, 2015) |
| " Conversely, recent studies showed that troglitazone, a PPARγ agonist, increases the cytotoxicity of DOX against breast cancer cells by up-regulating mitochondrial biogenesis." | 3.81 | Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts. ( Deus, CM; Nordgren, K; Oliveira, PJ; Skildum, A; Wallace, KB; Zehowski, C, 2015) |
| "We studied the roles of glycolysis and glutaminolysis following an acute reduction in mitochondrial membrane potential (Ψ(m)) induced by the thiazolidinedione troglitazone (TRO) and compared the responses with CCCP-induced depolarization in breast cancer derived MCF-7 and MDA-MB-231 cells as well as in the MCF-10A normal breast cell line." | 3.77 | Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: Relationship to mitochondrial membrane potential. ( Friday, E; Oliver, R; Turturro, F; Welbourne, T, 2011) |
| "Here, we demonstrate that troglitazone (Rezulin), a peroxisome proliferator-activated receptor agonist, acted in synergy with heregulin to induce massive cell death in breast cancer cells." | 3.77 | Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. ( Lee, BC; Lee, SB; Lee, YJ; Park, BH; Stolz, DB, 2011) |
| "In this study, we investigated the effect of the PPARgamma ligand, troglitazone, on telomerase activity in the MDA-MB-231 breast cancer cell line." | 3.76 | Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. ( Done, SJ; Harrington, LA; Nguyen, J; Rashid-Kolvear, F; Taboski, MA; Wang, DY, 2010) |
| " Surprisingly, we failed to demonstrate that MDA-MB-231 breast cancer cells undergo apoptosis when treated with sub-saturation doses of troglitazone and rosiglitazone, which are synthetic PPAR gamma ligands." | 3.75 | PPARgamma activation induces autophagy in breast cancer cells. ( Casimiro, MC; Lanza-Jacoby, S; Liang, B; Lisanti, MP; Pestell, RG; Wang, C; Wang, M; Whitaker-Menezes, D; Zhang, W; Zhou, J, 2009) |
| "We previously showed that troglitazone (TRO) induces a profound cellular acidosis in MCF-7 cells as a result of inhibiting Na(+)/H(+) exchanger (NHE)1-mediated acid extrusion and this was associated with a marked reduction in cellular proliferation." | 3.74 | Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na+/H+ exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7. ( Friday, E; Oliver, R; Turturro, F; Welbourne, T, 2007) |
| "In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and ciglitazone on cyclin D1 repression." | 3.73 | Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. ( Brueggemeier, RW; Chen, CS; Chen, KF; Huang, JW; Kulp, SK; Shapiro, CL; Shiau, CW; Yang, YT, 2005) |
| "The effect of epirubicin on inhibiting cell proliferation of breast cancer cells was enhanced by co-treatment with troglitazone in the range of 4 micromol/L to 24 micromol/L." | 3.73 | [Troglitazone sensitizes effect of epirubicin on breast cancer cells]. ( Lv, JH; Meng, ZX; Sun, JX; Sun, YJ, 2006) |
| " Because c-erbB family growth factor receptor 2 (HER2) overexpression is one of the most recognizable molecular dysfunctions in breast tumors, in the studies presented here, we explored the effect of HER2 overexpression on the status of PPARgamma expression and on the sensitivity of breast cancer cells to PPARgamma-ligand troglitazone-induced growth inhibition." | 3.72 | HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. ( Bagheri-Yarmand, R; Balasenthil, S; Barnes, CJ; Hortobagyi, G; Kumar, R; Sahin, AA; Yang, Z, 2003) |
| "We previously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells." | 3.72 | Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. ( Blaschke, F; Bruemmer, D; Herle, AJ; Hsueh, WA; Law, RE; Yin, F, 2004) |
| "The purpose of this study was to assess whether troglitazone (TRO) would induce cellular acidosis by inhibiting Na(+)/H(+) exchanger (NHE) 1 in breast carcinoma-derived cell lines and, if so, whether cellular acidosis would be associated with a reduction in proliferation." | 3.72 | Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. ( Fowler, R; Friday, E; Surie, D; Turturro, F; Welbourne, T, 2004) |
| "We studied the effects of low-, moderate-, and high-dose treatment of the PPARgamma ligands 15-deoxy-delta1214 prostaglandin J2 (15dPGJ2) and troglitazone (TGZ) on parameters of cell growth, differentiation, and apoptosis in the epithelial breast cancer cell line MDA-MB-231." | 3.71 | Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. ( Atsumi, G; Chilton, FH; Clay, CE; Fonteh, AN; High, KP; Namen, AM; Trimboli, AJ, 2001) |
| "We investigated the effects of a nuclear receptor system constituted by retinoid X receptor (RXR) and its heterodimer partner on the aromatase activity in a cultured MCF-7 human breast cancer cell line and also in human ovarian granulosa cells, using each selective ligand for retinoic acid receptor, RAR (TTNPB), retinoid X receptor, RXR (LG100268), PPARgamma (troglitazone), and vitamin D3 receptor (cholecalciferol)." | 3.71 | Regulation of aromatase by nuclear receptors. ( Goto, K; Mu, YM; Nawata, H; Nishi, Y; Nomura, M; Okabe, T; Takayanagi, R; Yanase, T, 2001) |
| "2‑Deoxyglucose (2‑DG) was more cytotoxic in CT26 cancer cells compared with T47D cells, despite a smaller suppression of glucose uptake." | 1.56 | Troglitazone exerts metabolic and antitumor effects on T47D breast cancer cells by suppressing mitochondrial pyruvate availability. ( Cho, YS; Jung, KH; Lee, JH; Lee, KH; Moon, SH; Park, JW, 2020) |
| "Breast cancer is the most prevalent cancer in women." | 1.38 | Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. ( Boisbrun, M; Chapleur, Y; Colin, C; Flament, S; Grillier-Vuissoz, I; Kuntz, S; Martin, H; Mazerbourg, S; Richert, L; Salamone, S, 2012) |
| "The treatment of human breast cancer cell lines with PPARgamma agonists is known to have antiproliferative effects but the role of PPARgamma activation in the process remains unclear." | 1.35 | Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. ( Boisbrun, M; Chapleur, Y; Flament, S; Grillier-Vuissoz, I; Lecomte, J; Mazerbourg, S; Salamone, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 19 (61.29) | 29.6817 |
| 2010's | 10 (32.26) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Salamone, S | 3 |
| Colin, C | 2 |
| Grillier-Vuissoz, I | 4 |
| Kuntz, S | 3 |
| Mazerbourg, S | 3 |
| Flament, S | 4 |
| Martin, H | 1 |
| Richert, L | 1 |
| Chapleur, Y | 4 |
| Boisbrun, M | 4 |
| Jung, KH | 1 |
| Lee, JH | 1 |
| Park, JW | 1 |
| Moon, SH | 1 |
| Cho, YS | 1 |
| Lee, KH | 1 |
| Colin-Cassin, C | 1 |
| Yao, X | 1 |
| Cerella, C | 1 |
| Chbicheb, S | 1 |
| Diederich, M | 1 |
| Deus, CM | 1 |
| Zehowski, C | 1 |
| Nordgren, K | 1 |
| Wallace, KB | 1 |
| Skildum, A | 2 |
| Oliveira, PJ | 1 |
| Pseftogas, A | 1 |
| Gonidas, C | 1 |
| Mosialos, G | 1 |
| Korkmaz, A | 1 |
| Tamura, H | 1 |
| Manchester, LC | 1 |
| Ogden, GB | 1 |
| Tan, DX | 1 |
| Reiter, RJ | 1 |
| Yu, HN | 2 |
| Noh, EM | 2 |
| Lee, YR | 2 |
| Roh, SG | 1 |
| Song, EK | 2 |
| Han, MK | 2 |
| Lee, YC | 2 |
| Shim, IK | 1 |
| Lee, SJ | 2 |
| Jung, SH | 2 |
| Kim, JS | 2 |
| Youn, HJ | 2 |
| Zhou, J | 1 |
| Zhang, W | 1 |
| Liang, B | 1 |
| Casimiro, MC | 1 |
| Whitaker-Menezes, D | 1 |
| Wang, M | 1 |
| Lisanti, MP | 1 |
| Lanza-Jacoby, S | 1 |
| Pestell, RG | 1 |
| Wang, C | 1 |
| Davies, GF | 1 |
| Ross, AR | 1 |
| Arnason, TG | 1 |
| Juurlink, BH | 1 |
| Harkness, TA | 1 |
| Lecomte, J | 2 |
| Rashid-Kolvear, F | 1 |
| Taboski, MA | 1 |
| Nguyen, J | 1 |
| Wang, DY | 1 |
| Harrington, LA | 1 |
| Done, SJ | 1 |
| Friday, E | 3 |
| Oliver, R | 2 |
| Welbourne, T | 3 |
| Turturro, F | 3 |
| Dornfeld, K | 1 |
| Wallace, K | 1 |
| Park, BH | 1 |
| Lee, SB | 1 |
| Stolz, DB | 1 |
| Lee, YJ | 1 |
| Lee, BC | 1 |
| Burgermeister, E | 1 |
| Tencer, L | 1 |
| Liscovitch, M | 1 |
| Burstein, HJ | 1 |
| Demetri, GD | 1 |
| Mueller, E | 1 |
| Sarraf, P | 1 |
| Spiegelman, BM | 1 |
| Winer, EP | 1 |
| Yang, Z | 1 |
| Bagheri-Yarmand, R | 1 |
| Balasenthil, S | 1 |
| Hortobagyi, G | 1 |
| Sahin, AA | 1 |
| Barnes, CJ | 1 |
| Kumar, R | 1 |
| Yin, F | 2 |
| Bruemmer, D | 1 |
| Blaschke, F | 1 |
| Hsueh, WA | 2 |
| Law, RE | 2 |
| Herle, AJ | 1 |
| Fowler, R | 1 |
| Surie, D | 1 |
| Huang, JW | 1 |
| Shiau, CW | 1 |
| Yang, YT | 1 |
| Kulp, SK | 1 |
| Chen, KF | 1 |
| Brueggemeier, RW | 1 |
| Shapiro, CL | 1 |
| Chen, CS | 1 |
| Murad, H | 1 |
| Collet, P | 1 |
| Huin-Schohn, C | 1 |
| Al-Makdissy, N | 1 |
| Kerjan, G | 1 |
| Chedotal, A | 1 |
| Donner, M | 1 |
| Devignes, MD | 1 |
| Becuwe, P | 1 |
| Schohn, H | 1 |
| Domenjoud, L | 1 |
| Dauça, M | 1 |
| Sun, JX | 1 |
| Meng, ZX | 1 |
| Lv, JH | 1 |
| Sun, YJ | 1 |
| Wang, PS | 1 |
| Chou, FS | 1 |
| Porchia, L | 1 |
| Saji, M | 1 |
| Pinzone, JJ | 1 |
| Lee, KS | 1 |
| Kwon, KB | 1 |
| Elstner, E | 1 |
| Müller, C | 1 |
| Koshizuka, K | 1 |
| Williamson, EA | 1 |
| Park, D | 1 |
| Asou, H | 1 |
| Shintaku, P | 1 |
| Said, JW | 1 |
| Heber, D | 1 |
| Koeffler, HP | 1 |
| Rubin, GL | 1 |
| Zhao, Y | 1 |
| Kalus, AM | 1 |
| Simpson, ER | 1 |
| Clay, CE | 1 |
| Namen, AM | 1 |
| Atsumi, G | 1 |
| Trimboli, AJ | 1 |
| Fonteh, AN | 1 |
| High, KP | 1 |
| Chilton, FH | 1 |
| Wakino, S | 1 |
| Liu, Z | 1 |
| Kim, S | 1 |
| Collins, AR | 1 |
| Van Herle, AJ | 1 |
| Yanase, T | 1 |
| Mu, YM | 1 |
| Nishi, Y | 1 |
| Goto, K | 1 |
| Nomura, M | 1 |
| Okabe, T | 1 |
| Takayanagi, R | 1 |
| Nawata, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer[NCT00923949] | Phase 2 | 1 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Study never published; terminated early due to low accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the number of participants with adverse events. For details about the adverse events see the adverse event module. (NCT00923949)
Timeframe: 58 days
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone | 1 |
1 trial available for troglitazone and Breast Cancer
| Article | Year |
|---|---|
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chromans; Disease Progre | 2003 |
30 other studies available for troglitazone and Breast Cancer
| Article | Year |
|---|---|
Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemis | 2012 |
Troglitazone exerts metabolic and antitumor effects on T47D breast cancer cells by suppressing mitochondrial pyruvate availability.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyg | 2020 |
PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Caspase 7; Cell Cycle; Cell Proli | 2015 |
Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Ce | 2015 |
Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Cell Line, Transfo | 2017 |
Combination of melatonin and a peroxisome proliferator-activated receptor-gamma agonist induces apoptosis in a breast cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chrom | 2009 |
Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2008 |
PPARgamma activation induces autophagy in breast cancer cells.
Topics: Animals; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Chromans; Epithelial Cells; Femal | 2009 |
Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Butyrates; Cell Line, Tumor | 2010 |
New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Topics: Antineoplastic Agents; Biotinylation; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell S | 2010 |
Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Differentiation; Chromans; E | 2010 |
Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: Relationship to mitochondrial membrane potential.
Topics: Breast Neoplasms; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chromans; Citric Acid Cycle; Female; Gl | 2011 |
Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell | 2011 |
Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromans; Drug Synergism; Fema | 2011 |
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveoli | 2003 |
HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azo Compounds; Blotting, Northern; Blotti | 2003 |
Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Cycle; Chromans; Enzyme Inhibito | 2004 |
Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines.
Topics: Acidosis; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Chromans; DNA; Femal | 2004 |
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromans; Cyclin D1; Down-Regulation; Female; Humans; PPAR gamma | 2005 |
Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells.
Topics: Alitretinoin; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chromans; Dimerizati | 2006 |
[Troglitazone sensitizes effect of epirubicin on breast cancer cells].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; C | 2006 |
Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na+/H+ exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7.
Topics: Acidosis; Breast Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Chroman | 2007 |
Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromans; Dose-Respon | 2008 |
Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells.
Topics: Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Physiological Phenomena; Chro | 2008 |
Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromans; | 2008 |
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.
Topics: Adenocarcinoma; Animals; Apoptosis; Breast; Breast Neoplasms; Cell Differentiation; Chromans; Genes, | 1998 |
Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
Topics: Adipose Tissue; Animals; Aromatase; Aromatase Inhibitors; Binding, Competitive; Breast; Breast Neopl | 2000 |
Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Differentiation; Cell Division; Chromans; Female; Huma | 2001 |
Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; CDC2-CDC28 Kinase | 2001 |
Regulation of aromatase by nuclear receptors.
Topics: Aromatase; Benzoates; Breast Neoplasms; Cholecalciferol; Chromans; Female; Gene Expression Regulatio | 2001 |